Oxford Pharmascience Group PLC OXP to exhibit at the Master Investor Show 2016 (0917W)

TIDMOXP

RNS Number : 0917W

Oxford Pharmascience Group PLC

22 April 2016

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

To exhibit at the Master Investor Show 2016

Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces it will be exhibiting at this year's Master Investor Show held at the Business Design Centre in Islington, London, on Saturday 23 April 2016.

The Company's CEO, Marcelo Bravo, will be presenting at the event at 3:30 p.m. and will be at stand number 63 throughout the day. The presentation has been uploaded to the Company's website at www.oxfordpharmascience.com.

Summarising recent progress, Marcelo Bravo said:

"Our lead NSAID products, OXPzero(TM) Ibuprofen and OXPzero(TM) Naproxen, are now at the commercialisation stage. We are very encouraged with the strong traction we are getting from some of the major potential partners in our discussions.

In addition to the recent confirmation from the MHRA on the simplified regulatory pathway for OXPzero(TM) Ibuprofen, which we believe will also apply to OXPzero(TM) Naproxen, we are continuing to progress our other pipeline opportunities, including Aspirin and statins. Our strong financial position supports our combined strategy of commercialising our NSAID assets and platform and advancing our other pipeline compounds."

A short update video is available at the following link below:

http://brrmedia.co.uk/event/141808

For further information:

Oxford Pharmascience Group Plc

   Marcelo Bravo, Chief Executive          [phone] 

N+1 Singer (Nominated Adviser & Broker)

   Aubrey Powell / Jen Boorer                 [phone] 

Redleaf Communications

   Hannah Nicolas / Lara Pyliotis           [phone] 

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers, but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines, the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCMMGZDMZVGVZM

(END) Dow Jones Newswires

April 22, 2016 07:18 ET (11:18 GMT)